Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.
Industries
Nr. of Employees
medium (51-250)
Progenics Pharmaceuticals
Tarrytown, New York, United States, North America
Products
PNT2002
A small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 3 clinical trials.
LNTH-1095
A small molecule PSMA-targeted 131I-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 2 clinical trials.
LNTH-1404
A Tc-99m-labeled molecule used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer and metastases, currently in Phase 3 clinical trials.
PSMA-TAC
A PSMA-targeted antibody in initial development for metastatic castration-resistant prostate cancer, currently in Phase 1 clinical trials.
LNTH-1558
A small molecule PSMA-targeted agent in pre-clinical development for prostate cancer.
PNT2003
A somatostatin receptor-targeted radioligand therapy with 177Lu for gastroenteropancreatic neuroendocrine tumors, currently in regulatory filing stage.
PNT2002
A small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 3 clinical trials.
LNTH-1095
A small molecule PSMA-targeted 131I-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 2 clinical trials.
LNTH-1404
A Tc-99m-labeled molecule used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer and metastases, currently in Phase 3 clinical trials.
PSMA-TAC
A PSMA-targeted antibody in initial development for metastatic castration-resistant prostate cancer, currently in Phase 1 clinical trials.
LNTH-1558
A small molecule PSMA-targeted agent in pre-clinical development for prostate cancer.
PNT2003
A somatostatin receptor-targeted radioligand therapy with 177Lu for gastroenteropancreatic neuroendocrine tumors, currently in regulatory filing stage.